CytomX Therapeutics is a technology company.
CytomX Therapeutics has raised $61.0M across 3 funding rounds.
Key people at CytomX Therapeutics.
CytomX Therapeutics has raised $61.0M in total across 3 funding rounds.
Key people at CytomX Therapeutics.
CytomX Therapeutics has raised $61.0M in total across 3 funding rounds.
CytomX Therapeutics's investors include Canaan Partners, Pivotal bioVenture Partners, SV Health Investors, Third Rock Ventures.
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing Probody® therapeutics, which are conditionally activated biologics designed to localize activation in the tumor microenvironment for enhanced safety and efficacy in cancer treatment.[1][2] The company builds novel antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and cytokines like CX-2051 (anti-EpCAM ADC for epithelial cancers such as colorectal), CX-801 (IFN alpha-2b for melanoma and other tumors), CX-904 (EGFR/CD3 bispecific), and others in its pipeline, serving patients with advanced solid tumors and partnering with firms like Amgen, Bristol Myers Squibb, Regeneron, Moderna, and Merck.[1][3] It solves the problem of potent anti-cancer agents' toxicity to healthy tissues by masking them until they reach tumors, opening therapeutic windows for previously undruggable targets; with 121 employees and multiple Phase 1 trials ongoing, growth momentum includes initial data readouts for CX-2051 in H1 2025 and CX-801 in H2 2025.[1][3]
Founded in 2008 in South San Francisco, California, CytomX emerged from pioneering research into conditional activation technologies to address limitations in oncology biologics, leveraging the Probody platform for tumor-specific drug activation.[1][2] Key scientific leaders include experts like those from Genentech/Roche (e.g., developers of ADCs like polatuzumab vedotin and bispecifics like mosunetuzumab), ImmunoGen (ADC innovator behind Kadcyla®), and academic researchers in tumor immunology and immunotherapy, though specific founders are not detailed in available profiles.[4] Early traction built through strategic collaborations with major biopharma (Amgen, Astellas, BMS, Regeneron, Moderna) and its 2015 IPO, evolving from preclinical validation to a deep clinical pipeline advancing best-in-class and first-in-class therapies.[1][3]
CytomX rides the explosive growth in precision oncology, particularly ADCs and bispecifics, where the market is projected to expand amid demands for safer, tumor-selective therapies amid rising cancer incidence.[1][3] Timing is ideal post-2020s immuno-oncology boom, as limitations of systemic toxins (e.g., narrow windows for cytokines or EpCAM) create opportunities for conditional activation to complement checkpoints like PD-1 and next-gen modalities.[2][3] Market forces favoring it include biopharma's push for differentiated assets via partnerships and the shift toward "cold" tumor activation in immuno-resistant cancers; CytomX influences the ecosystem by licensing its platform, co-developing with giants, and pioneering Probody tech that could redefine biologic safety profiles.[1][4]
CytomX is poised for inflection with 2025 Phase 1 data readouts from CX-2051 and CX-801, potentially validating the Probody platform and unlocking partnerships or advancement to later stages.[3] Trends like ADC dominance, bispecific expansion, and combo immuno-therapies will shape its path, with success hinging on biomarker data demonstrating superior indices over standards.[3] Influence may evolve toward platform leadership if readouts succeed, expanding beyond oncology or amplifying via more big-pharma deals, ultimately revolutionizing cancer care by safely unleashing potent biologics—as a different kind of biopharma intent on destroying cancer, differently.[2]
CytomX Therapeutics has raised $61.0M across 3 funding rounds. Most recently, it raised $20.0M Series C in January 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2015 | $20.0M Series C | Canaan Partners, Pivotal bioVenture Partners, SV Health Investors, Third Rock Ventures | |
| Jul 1, 2012 | $11.0M Series B | Canaan Partners, Pivotal bioVenture Partners, SV Health Investors, Third Rock Ventures | |
| Sep 1, 2010 | $30.0M Series B | SV Health Investors, Third Rock Ventures |
